Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
4 Chronic Kidney Disease The FLOW trial randomized 3,534 patients with chronic kidney disease and type 2 diabetes and started treating them with s.c. The study was terminated early because benefits were already significantly visible by October 2023. semaglutide 1.0 mg or placebo in 2019. mg is not recommended. mg is not recommended.
Let's personalize your content